Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. on April 26, 2021, covering an event that occurred on April 23, 2021. The company is incorporated in Delaware and its common stock trades on the New York Stock Exchange under the symbol RCUS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate transaction rather than financial performance.
Material Changes
The material event reported is a private transaction involving company insiders:
- Dr. Yasunori Kaneko, a director of Arcus Biosciences, purchased 4,133 shares of Arcus common stock.
- The shares were sold by Dr. William Grossman, the company's Chief Medical Officer.
- The transaction represented approximately 1.6% of the total shares either owned or that may be acquired by Dr. Grossman upon exercise of vested and exercisable options.
- The sale was executed by Dr. Grossman as part of his tax planning strategy.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The information provided in Item 7.01 is intended to be furnished and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the total number of shares owned or exercisable by Dr. William Grossman to confirm the 1.6% calculation.
- Review the company's most recent 10-Q or 10-K for actual financial performance metrics, as this 8-K does not contain them.
- Confirm the current trading price of RCUS on the NYSE to assess the monetary value of the 4,133 shares traded.